The Role of Ankaferd Blood Stopper and Oxytocin as Potential Therapeutic Agents in Endometriosis: A Rat Model
| Autor: | Gurkan Yigitturk, Murat Ulukus, Ismet Hortu, Gokay Ozceltik, Elif Karadadaş, Oytun Erbaş |
|---|---|
| Přispěvatelé: | Ege Üniversitesi, MÜ, Tıp Fakültesi, Temel Tıp Bilimleri Bölümü, Yiğittürk, Gürkan |
| Rok vydání: | 2020 |
| Předmět: |
Vascular Endothelial Growth Factor A
endometriosis Necrosis Endometriosis Oxytocin Biochemistry Rats Sprague-Dawley Andrology chemistry.chemical_compound oxytocin Biopsy Genetics medicine Animals Chemokine CCL2 medicine.diagnostic_test Plant Extracts Tumor Necrosis Factor-alpha business.industry Monocyte Peritoneal fluid medicine.disease cytokines Rats Vascular endothelial growth factor Disease Models Animal Ankaferd Blood Stopper medicine.anatomical_structure chemistry Cytokines Immunohistochemistry Female medicine.symptom business medicine.drug |
| Zdroj: | Current Medical Science. 40:556-562 |
| ISSN: | 2523-899X 2096-5230 |
| Popis: | WOS: 000549619600020 PubMed ID: 32681259 To evaluate the potential effect of Ankaferd Blood Stopper (ABS) and oxytocin (OT) in an experimental endometriosis model, 18 female Sprague Dawley rats were used in this study. The animals were divided randomly into three groups after surgical induction of endometriosis: group 1: control group (isotonic NaCl, 1 mL/kg/day, intramuscular,n=6); group 2: OT group (OT, 80 U/kg/day, intramuscular,n=6); group 3: ABS group (ABS, 1.5 mL/kg/day, intraperitoneal,n=6). Each group was treated for four weeks (two times per week). Volumes of endometriotic explants were measured in biopsy samples for histopathological analysis. Vascular endothelial growth factor (VEGF), monocyte chemotactic protein-1 (MCP-1), and tumour necrosis factor (TNF-alpha) levels were measured in plasma and peritoneal fluid. Endometriotic explant volumes were significantly decreased after OT administration (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full text from SpringerLink